Newsmeme!
Discover News you didn't know existed
Summer is officially here. Already temperatures are sky high and people are outside enjoying summer activities. But too much sun could have lasting effects.
Van Andel Research Institute (VARI) investigators have identified a gene that could be an important therapeutic target in the treatment of the most aggressive forms of breast cancer. Currently, patients with these cancers have few treatment options.
Whether one still has acne or is just left with ugly scars, the answer to remove acne scars is here. Treatment with enzymes and skin regeneration accelerators from an organic naturally occurring serum revitalize and repair damaged skin tissues and restore healthy skin. (PRWeb Jul 9, 2009) Read the full story at http://www.prweb.com/releases/2009/07/prweb2617194.htm
Whether one still has acne or is just left with ugly scars, the answer to remove acne scars is here. Treatment with enzymes and skin regeneration accelerators from an organic naturally occurring serum revitalize and repair damaged skin tissues and restore healthy skin.
Investigators have identified a gene that could be an important therapeutic target in the treatment of the most aggressive forms of breast cancer. Currently, patients with these cancers have few treatment options.
Van Andel Research Institute (VARI) investigators have identified a gene that could be an important therapeutic target in the treatment of the most aggressive forms of breast cancer.
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the results of the long-term, 5-year study of Lantus(R) (insulin glargine [rDNA] injection) versus NPH insulin on progression of retinopathy in patients with type 2 diabetes, published on-line in Diabetologia (DOI 10.1007/s00125-009-1415-7) showed similar effects on retinopathy and overall safety in the two treatment groups.
/PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the results of the long-term, 5-year study of Lantus(R) (insulin glargine [rDNA] injection) versus NPH insulin on progression of retinopathy in patients with type 2 diabetes, published on-line in Diabetologia
Sanofi-aventis announced today that the results of the long-term, 5-year study of LantusĀ® versus NPH insulin on progression of retinopathy in patients with type 2 diabetes, published on-line in Diabetologia showed similar effects on retinopathy and overall safety in the two treatment groups.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |